Table 2.
Clinical and demographic features of RespondersT13 and NON-RespondersT13
| Total | RespondersT13 | NON-RespondersT13 | p-value | |
|---|---|---|---|---|
| n | 77 | 50 | 27 | - |
| Age, (years, m ± sd) | 49.8 ± 9.5 | 49.4 ± 9.4 | 50.6 ± 9.7 | 0.967 |
| Females, n (%) | 55 (71.4) | 33 (66.0) | 22 (81.5) | 0.191 |
| Age at headache onset (years, m ± sd) | 14.5 ± 6.9 | 15.0 ± 7.3 | 13.6 ± 6.2 | 0.300 |
| Years lived with migraine (years, m ± sd) | 35.6 ± 10.8 | 34.8 ± 10.5 | 36.9 ± 11.2 | 0.701 |
| Years lived with chronic migraine (years, m ± sd) | 13.1 ± 10.3 | 12.6 ± 10.0 | 14.2 ± 12.6 | 0.424 |
| Migraine with aura, n (%) | 13 (16.9) | 10 (20.0) | 3 (11.1) | 0.525 |
| MOH, n (%) | 71 (92.2) | 40 (95.2) | 31 (88.6) | 0.402 |
| Previous detoxification for MOH, n (%) | 69 (89.6) | 45 (90.0) | 24 (88.9) | 0.879 |
| Preventive treatment | ||||
| Patients on preventive treatment at T0, n (%) | 42 (54.5) | 28 (56.0) | 14 (51.9) | 0.812 |
| Number of previously failed preventive treatments (m ± sd) | 3.8 ± 1.2 | 3.7 ± 1.3 | 4.0 ± 1.0 | 0.439 |
| Previous BoNT-A treatment, n (%) | 47 (61.0) | 27 (54.0) | 20 (74.1) | 0.094 |
| Classes of acute drugs | ||||
| NSAIDs, n (%) | 12 (15.6) | 7 (16.7) | 5 (14.3) | 0.408 |
| Triptans, n (%) | 20 (26.0) | 9 (21.4) | 11 (31.4) | |
| Combination, n (%) | 4 (5.2) | 1 (2.4) | 3 (8.6) | |
| Multiple drug classes, n (%) | 41 (53.2) | 25 (59.5) | 16 (45.7) | |
| Comorbidities | ||||
| Hypertension, n (%) | 19 (24.7) | 11 (26.2) | 8 (22.9) | 0.795 |
| Anxiety, n (%) | 22 (28.6) | 12 (28.6) | 10 (28.6) | 0.999 |
| Depression, n (%) | 4 (5.2) | 2 (4.8) | 2 (5.7) | |
| Anxiety and depression, n (%) | 18 (23.4) | 10 (12.9) | 8 (10.3) | |
| vInsomnia, n (%) | 33 (42.9) | 18 (42.9) | 15 (42.9) | 1.000 |
| Migraine features at baseline | ||||
| Monthly headache days (m ± sd) | 24.6 ± 4.8 | 24.3 ± 4.9 | 25.2 ± 4.6 | 0.545 |
| Monthly migraine days (m ± sd) | 23.0 ± 5.1 | 22.9 ± 4.9 | 23.1 ± 5.4 | 0.861 |
| Monthly days of acute drugs intake (m ± sd) | 20.8 ± 7.6 | 21.0 ± 7.3 | 20.3 ± 8.2 | 0.534 |
| Monthly doses of acute drugs intake (m ± sd) | 34.7 ± 29.9 | 33.8 ± 28.6 | 36.3 ± 32.6 | 0.898 |
| Questionnaires at baseline | ||||
| MIDAS (m ± sd) | 77.5 ± 69.0 | 74.0 ± 70.7 | 84.0 ± 66.5 | 0.452 |
| Mean headache intensity (m ± sd) | 8.0 ± 6.4 | 8.3 ± 7.9 | 7.5 ± 1.1 | 0.349 |
| HIT-6 (m ± sd) | 66.8 ± 5.8 | 66.0 ± 5.7 | 68.3 ± 5.6 | 0.113 |
| ASC-12 (allodynia) (m ± sd) | 6.4 ± 5.1 | 6.1 ± 5.5 | 6.8 ± 4.4 | 0.707 |
| MSQ (m ± sd) | 34.4 ± 18.1 | 36.8 ± 16.0 | 29.7 ± 21.0 | 0.190 |
| General Health (0–100) (m ± sd) | 54.4 ± 22.3 | 59.2 ± 19.4 | 45.6 ± 2 4.9 | 0.022 |
| HADS-A (m ± sd) | 6.51 ± 4.03 | 6.0 ± 3.9 | 7.4 ± 4.1 | 0.079 |
| HADS-D (m ± sd) | 6.39 ± 4.40 | 5.6 ± 4.3 | 7.8 ± 4.3 | 0.031 |
Legend: RespondersT13: Patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). NON-RespondersT13: Patients with a MMDs reduction from baseline < 50% in the last 4 weeks of observation period (after 13 erenumab administrations).
CM Chronic migraine, CM + MOH Chronic migraine and medication overuse headache, BoNT-A Onabotulinumtoxin-A, MIDAS MIgraine Disability Assessment, HIT-6 Headache Impact Test-6, ASC-12 Allodynia Symptoms Checlist, MSQ Migraine-Specific Quality of Life Questionnaire, HADS Hospital Anxiety and Depression Scale. Data are presented as means ± standard deviations (m ± sd) or absolute values (percentages).